Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sexual and Gender Minorities | 3 | 2023 | 262 | 0.800 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2024 | 206 | 0.690 |
Why?
|
| HIV Infections | 4 | 2024 | 1018 | 0.640 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 114 | 0.590 |
Why?
|
| Cognitive Dysfunction | 2 | 2025 | 209 | 0.340 |
Why?
|
| Homosexuality, Male | 3 | 2024 | 342 | 0.330 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 55 | 0.270 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2008 | 125 | 0.250 |
Why?
|
| Vascular Surgical Procedures | 1 | 2008 | 170 | 0.250 |
Why?
|
| Stroke Rehabilitation | 1 | 2025 | 54 | 0.220 |
Why?
|
| Radiology Information Systems | 1 | 2024 | 81 | 0.210 |
Why?
|
| Frontal Lobe | 2 | 2014 | 128 | 0.190 |
Why?
|
| Intimate Partner Violence | 1 | 2023 | 36 | 0.190 |
Why?
|
| Sexual Behavior | 2 | 2022 | 340 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 68 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2024 | 211 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2023 | 186 | 0.160 |
Why?
|
| Cognition | 4 | 2025 | 669 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2024 | 687 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 446 | 0.160 |
Why?
|
| Schizophrenia | 1 | 2023 | 558 | 0.150 |
Why?
|
| Pharmacogenomic Variants | 1 | 2019 | 46 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2678 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 826 | 0.130 |
Why?
|
| Stroke | 1 | 2025 | 1167 | 0.120 |
Why?
|
| Young Adult | 4 | 2023 | 7568 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 913 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 30 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 391 | 0.100 |
Why?
|
| Corpus Callosum | 1 | 2014 | 58 | 0.100 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2014 | 69 | 0.100 |
Why?
|
| China | 2 | 2024 | 277 | 0.090 |
Why?
|
| Male | 8 | 2025 | 47257 | 0.090 |
Why?
|
| Temporal Lobe | 1 | 2013 | 188 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1077 | 0.090 |
Why?
|
| Humans | 12 | 2025 | 98362 | 0.080 |
Why?
|
| Adolescent | 2 | 2021 | 10137 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 832 | 0.080 |
Why?
|
| Aged | 7 | 2025 | 21844 | 0.080 |
Why?
|
| Taiwan | 2 | 2023 | 27 | 0.080 |
Why?
|
| Pneumocephalus | 1 | 2009 | 12 | 0.080 |
Why?
|
| Embolism, Air | 1 | 2009 | 21 | 0.080 |
Why?
|
| Adult | 5 | 2023 | 29587 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2009 | 296 | 0.060 |
Why?
|
| Middle Aged | 6 | 2025 | 29532 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 2056 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2574 | 0.060 |
Why?
|
| Nutritional Status | 1 | 2025 | 84 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2025 | 171 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 7418 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2025 | 372 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2023 | 75 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 167 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2025 | 3612 | 0.050 |
Why?
|
| Executive Function | 1 | 2023 | 115 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 180 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2024 | 720 | 0.040 |
Why?
|
| Neuropsychological Tests | 2 | 2014 | 567 | 0.040 |
Why?
|
| Female | 6 | 2025 | 51756 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 992 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 4044 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 314 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 158 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 1178 | 0.040 |
Why?
|
| Prognosis | 1 | 2008 | 4126 | 0.040 |
Why?
|
| Liver | 1 | 2024 | 1230 | 0.040 |
Why?
|
| Hospitalization | 1 | 2025 | 988 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 602 | 0.040 |
Why?
|
| Genotype | 2 | 2014 | 1892 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1393 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 619 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2019 | 263 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 2471 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 2003 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1035 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 867 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2008 | 9770 | 0.030 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 33 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 213 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2008 | 11039 | 0.020 |
Why?
|
| Organ Size | 1 | 2013 | 370 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 335 | 0.020 |
Why?
|
| Reference Values | 1 | 2013 | 608 | 0.020 |
Why?
|
| Heterozygote | 1 | 2014 | 392 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2014 | 239 | 0.020 |
Why?
|
| Risk Factors | 1 | 2023 | 6271 | 0.020 |
Why?
|
| United States | 1 | 2024 | 8258 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 1859 | 0.020 |
Why?
|
| Alleles | 1 | 2013 | 1163 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1322 | 0.020 |
Why?
|
| Subarachnoid Space | 1 | 2009 | 17 | 0.020 |
Why?
|
| Brain Infarction | 1 | 2009 | 23 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 75 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 295 | 0.020 |
Why?
|
| Bronchi | 1 | 2009 | 229 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 583 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 342 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2009 | 416 | 0.010 |
Why?
|
| Lung | 1 | 2009 | 1408 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 1539 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 2439 | 0.010 |
Why?
|